Two patients with chronic hepatitis C virus (HCV) genotype 2b infection were studied. They responded biochemically to interferon (IFN) but had early virological and later biochemical relapse. The HCV quasispecies equilibrium in these patients was studied by a combination of cloning, sequencing and construction of phylogenetic trees. Another patient with chronic HCV genotype 2b infection was followed every 6 months for 30 months (including one episode of biochemical exacerbation) to serve as the control. Quasispecies equilibrium drifted during IFN therapy but moved back in the direction of the original equilibrium during biochemical relapse. In the control patient, there was no significant drifting throughout the follow-up period. These data suggest that IFN therapy exerts selective pressure on HCV quasispecies equilibrium.
References
1.
ChooQ.L., KuoG., WeinerA.J., OverbyL.R., BradleyD.W., & HoughtonM.Isolation of a cDNA clone derived from a blood borne non-A, non-B hepatitis genome. Science1989; 244: 359–362.
2.
KuoG., ChooQ.L., AlterH.J., GitnikG.L., RedekerA.G., PurcellR.H., MiyamuraT, DienstagJ.L., AlterM.J., StevensC.E.An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science1989; 244: 362–364.
3.
DavisG.L., & LauJ.Y.N.Hepatitis C virus. In Bockus's Series of Gastroenterology, 5th edn, 1994, pp. 2082–2114. Edited by HaubrichW.S., SchaffnerF., & BerkJ.E.Philadelphia: WB Saunders.
4.
DavisG.L., BalartL.A., SchiffE.R., LindsayK., BodenheimerH.C., PerrilloR.P., CareyW, JacobsonI.M., PayneJ., DienstagJ.L.Treatment of chronic hepatitis C with recombinant interferon alfa. New England Journal of Medicine1989; 321: 1501–1506.
5.
Di BisceglieA.M., MartinP., KassianidesC., Lisker-MelmanM., MurrayL., WaggonerJ., GoodmanZ., BanksS.M., & HoofnagleJ.H.Recombinant interferon alfa therapy for chronic hepatitis C. New England Journal of Medicine1989; 321: 1506–1510.
6.
LauJ.Y.N., MizokamiM., OhnoT., DiamondD., KniffenJ., & DavisG.L.Discrepancy between biochemical and virological response to interferon-α therapy in chronic hepatitis C. Lancet1993; 342: 1208–1209.
7.
HigashiY., KakumuK., YoshiokaK., WakitaT., MizokamiM., OhbaK., ItoY., IshikawaT., TakayanagiM., & NagaiY.Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo. Virology1993; 197: 659–668.
8.
MizokamiM., LauJ.Y.N., SuzukiK., NakanoT., & GojoboriT.Differential sensitivity of hepatitis C virus quasispecies to interferon-α therapy. Journal of Hepatology1994; 21: 884–886.
9.
LauJ.Y.N., MizokamiM., KolbergJ.A., DavisG.L., PrescottL.E., OhnoT., PerrilloR.P., LindsayK., GishR.G., QianK.P.Application of six hepatitis C virus genotyping systems to sera from patients with chronic hepatitis C in United States. Journal of Infectious Diseases1995; 171: 281–289.
10.
LauJ.Y.N., DavisG.L., KniffenJ., QianK.P., UrdeaM.S., ChanC.S., MizokamiM., NeuwaldP.D., & WilberJ.C.Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet1993; 341: 1501–1504.
11.
LauJ.Y.N., SimmondsP., & UrdeaM.S.Implications of variations of ‘conserved’ regions of hepatitis C virus genome. Lancet1995; 346: 425–426.
12.
SuzukiK., MizokamiM., LauJ.Y.N., MizoguchiN., KatoK., MizunoY., SodeyamaT., KiyosawaK., & GojoboriT.Confirmation of hepatitis C virus transmission through needlestick accident by molecular evolutionary analysis. Journal of Infectious Diseases1994; 170: 1575–1578.
13.
Gonzalez-PeraltaR.P., QianK.P., SheJ. Y., DavisG.L., OhnoT., MizokamiM., & LauJ.Y.N.Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C virus infection. Journal of Medical Virology1996; 49: 242–247.
14.
GojoboriT., IshiiK., & NeiM.Estimation of average number of nucleotide substitution when the rate of the substitution varies with nucleotide. Journal of Molecular Evolution1982; 18: 414–423.
15.
MizokamiM., GobojoriT., & LauJ.Y.N.Molecular evolutinary medicine - its application to the study of hepatitis C virus. Gastroenterology1994; 107: 1181–1182.
